Buy Torvacard (Atorvastatin) pills

Torvacard (Atorvastatin) pills

61448USD

Description

Features

Reviews

Instructions for Torvacard (Atorvastatin) pills

English product name
Torvacard®

Release form
tab. film sheath, 10 mg: 30, 60 or 90 pcs.
tab. film coating, 20 mg: 30, 60 or 90 pcs.
tab. film sheath, 40 mg: 30, 60 or 90 pcs.

Description Torvacard

The tablets are covered with a film shell from white to almost white in color, oval and double-convex.

1 tab.
atorvastatin calcium 41.36 mg,
which corresponds to the content of atorvastatin 40 mg

Auxiliary substances Atorvastatin:
magnesium oxide, microcrystalline cellulose, monohydrate lactose, sodium croskarmellosis, low-substituted hyprolose, colloidal silicon dioxide, magnesium stearate.

The film shell consists of hypromellose 2910/5, macrogol 6000, titanium dioxide, talc.

10 pcs - blister packs (3) - cardboard packs.
10 pcs - blister packs (6) - cardboard packs.
10 pcs - blister packs (9) - cardboard packs.

ATC codes
C10AA05 Atorvastatin

Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug

Active substance
atorvastatin

Pharmacotherapy group Torvacard

Hypolipidemic agent - reductase inhibitor GMG-CoA

Storage Conditions
The drug should be stored in a place inaccessible to children.

Best before date Atorvastatin
Shelf life is 4 years.

Testimony Torvacard

combined with a diet to reduce elevated levels of total HS, HS-LDL,
apolipoprotein B and triglycerides and increase Hs-HDL levels in patients with primary hypercholesterolemia,
heterozygous familial and nonfamilial hypercholesterolemia and combined (mixed) hyperlipidemia (types IIa and IIb
Fredricson);
combined with a diet for patients with elevated serum levels of triglycerides (Type IV Fredrikson) and
dysbetalipoproteinemia patients (Type III Fredrikson), in which diet therapy does not give adequate effect;
to reduce the levels of total Hs and Hs-LDL in patients with homozygous familial hypercholesterolemia, when diet therapy
and other non-pharmacological treatments are not sufficiently effective (as a complement to hypolipidemic therapy,
including autohemotransfusion of LDL-treated blood);
Cardiovascular diseases (in patients with elevated risk factors for IBS - elderly over 55 years,
smoking,
arterial hypertension,
diabetes mellitus,
peripheral vascular diseases,
stroke,
left ventricular hypertrophy,
protein/albuminuria, IBS in the next of kin),
including,
on the background of dylipidemia,
secondary prevention to reduce the total risk of death,
myocardial infarction,
stroke,
repeated hospitalization for angina and the need for revascularization.

Method of use, course and dosage Torvacard

Before prescribing Torvakard®, a patient should be recommended a standard hypolipidemic diet, which he should continue to follow throughout the entire period of therapy.

The initial dose is on average ten mg once per day. The dose varies from ten to eighty mg once a day. The drug can be taken at any time of the day, regardless of the time of eating. The dose is selected taking into account the initial levels of Hs-LDL, the purpose of the therapy and the individual effect. At the beginning of the treatment and/or during the dose increase of Torvakard® it is necessary to control the lipid levels in blood plasma every two to four weeks and to corrugate the dose accordingly. The maximum daily dose is 80 mg per dose.

Pharmacological effect Torvacard

Hypolipidemic preparation from the group of statins. A selective, competitive inhibitor of GMG-CoA reductase, an enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A into mevalonic acid, a precursor to steroids including cholesterol.
the synthesis of cholesterol in the liver and the increase in the number of LDL receptors in the liver on the cell surface, which leads to an increase in LDL uptake and catabolism.
Atorvastatin reduces cholesterol (Hs) and lipoprotein levels in blood plasma by inhibiting GMG-CoA reductase